Literature DB >> 22974779

Optimal imaging protocols for lung cancer staging: CT, PET, MR imaging, and the role of imaging.

Narinder S Paul1, Sebastian Ley, Ur Metser.   

Abstract

Chest radiography, the most commonly performed imaging technique for the detection of lung disease, is limited in accurately detecting early lung cancer. The main imaging modality for the staging of lung cancer is computed tomography (CT), supplemented by positron emission tomography (PET), usually as a hybrid technique in conjunction with CT (PET/CT). Magnetic resonance (MR) imaging is a useful diagnostic tool for specific indications and has the advantage of not using ionizing radiation. This article discusses the optimal imaging protocols for lung cancer staging using CT, PET (PET/CT), and MR imaging, and the role of imaging in patient management. Crown
Copyright © 2012. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22974779     DOI: 10.1016/j.rcl.2012.06.007

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  14 in total

Review 1.  The clinical evaluation of novel imaging methods for cancer management.

Authors:  Lalitha K Shankar
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

2.  Multimodality molecular imaging of the lung.

Authors:  Delphine L Chen; Paul E Kinahan
Journal:  Clin Transl Imaging       Date:  2014-10-16

3.  PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis.

Authors:  Ray Y Chen; Lori E Dodd; Myungsun Lee; Praveen Paripati; Dima A Hammoud; James M Mountz; Doosoo Jeon; Nadeem Zia; Homeira Zahiri; M Teresa Coleman; Matthew W Carroll; Jong Doo Lee; Yeon Joo Jeong; Peter Herscovitch; Saher Lahouar; Michael Tartakovsky; Alexander Rosenthal; Sandeep Somaiyya; Soyoung Lee; Lisa C Goldfeder; Ying Cai; Laura E Via; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry
Journal:  Sci Transl Med       Date:  2014-12-03       Impact factor: 17.956

4.  The impact on the prognosis of unsuspected N2 disease in non-small-cell lung cancer: indications for thorough mediastinal staging in the modern era.

Authors:  Ryosuke Tachi; Aritoshi Hattori; Takeshi Matsunaga; Kazuya Takamochi; Shiaki Oh; Kenji Suzuki
Journal:  Surg Today       Date:  2016-07-21       Impact factor: 2.549

5.  FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.

Authors:  Hyun Woo Chung; Kye Young Lee; Hee Joung Kim; Wan Seop Kim; Young So
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-06       Impact factor: 4.553

6.  Squamous cell carcinoma of pancreas: an unusual site of relapse from early-stage lung cancer: 12-month postsurgery.

Authors:  Anand Sharma; Maryam Alfa-Wali; Manuel Rodriguez-Justo; Andreas Polychronis
Journal:  BMJ Case Rep       Date:  2013-04-22

7.  (99m)Tc-3P-RGD2 micro-single-photon emission computed tomography/computed tomography provides a rational basis for integrin αvβ3-targeted therapy.

Authors:  Tong Fu; Wei Qu; Fan Qiu; Yan Li; Guoqiang Shao; Wei Tian; Zichun Hua; Yingjian Zhang; Feng Wang
Journal:  Cancer Biother Radiopharm       Date:  2014-10-06       Impact factor: 3.099

Review 8.  Magnetic resonance imaging for N staging in non-small cell lung cancer: A systematic review and meta-analysis.

Authors:  Yuanyuan Zhang; Qin Qin; Baosheng Li; Juan Wang; Kun Zhang
Journal:  Thorac Cancer       Date:  2015-01-08       Impact factor: 3.500

Review 9.  Monitoring and management of lung cancer patients following curative-intent treatment: clinical utility of 2-deoxy-2-[fluorine-18]fluoro-d-glucose positron emission tomography/computed tomography.

Authors:  Shigeki Sawada; Hiroshi Suehisa; Tsuyoshi Ueno; Ryujiro Sugimoto; Motohiro Yamashita
Journal:  Lung Cancer (Auckl)       Date:  2016-04-27

10.  SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer.

Authors:  G Fernández-Pérez; R Sánchez-Escribano; A M García-Vicente; A Luna-Alcalá; J Ceballos-Viro; R C Delgado-Bolton; J C Vilanova-Busquets; P Sánchez-Rovira; M P Fierro-Alanis; R García-Figueiras; J E Alés-Martínez
Journal:  Clin Transl Oncol       Date:  2017-12-18       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.